A5067370868- Ocular Diseases and Behçet’s Syndrome
- Retinal and Optic Conditions
- Systemic Lupus Erythematosus Research
- Vasculitis and related conditions
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Platelet Disorders and Treatments
- Long-Term Effects of COVID-19
- Pituitary Gland Disorders and Treatments
- Osteomyelitis and Bone Disorders Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- Adrenal and Paraganglionic Tumors
- Chronic Lymphocytic Leukemia Research
- Cerebral Venous Sinus Thrombosis
- Renal Diseases and Glomerulopathies
- IgG4-Related and Inflammatory Diseases
- Cardiac Arrhythmias and Treatments
- Autoimmune and Inflammatory Disorders Research
- Bone Tumor Diagnosis and Treatments
- Yersinia bacterium, plague, ectoparasites research
- Gestational Diabetes Research and Management
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cardiovascular Health and Disease Prevention
- Clostridium difficile and Clostridium perfringens research
Inserm
2020-2024
Sorbonne Université
2020-2024
Pitié-Salpêtrière Hospital
2020-2024
Assistance Publique – Hôpitaux de Paris
2020-2024
Centre National de la Recherche Scientifique
2022-2023
Centre de Référence des Maladies Autoinflammatoires et des Amyloses
2020-2023
University of Abou Bekr Belkaïd
2015-2023
Collaborative Group (United States)
2020
Immunologie - Immunopathologie - Immunothérapie
2020
Université Paris Cité
2020
Type I cryoglobulinemia (CG) accounts for 10%-15% of all cryoglobulinemias and are exclusively seen in clonal proliferative hematologic conditions. In this multicenter nationwide cohort study, we analyzed the prognosis long-term outcomes 168 patients with type CG (93 (55.4%) IgM 75 [44.6%] IgG). Five- 10-year event-free survivals (EFS) were 26.5% (95% CI 18.2%-38.4%) 20.8% 13.1%-33.1%), respectively. multivariable analysis, factors associated poorer EFS renal involvement (HR: 2.42, 95%...
BackgroundCyclophosphamide and infliximab are recommended as induction therapies for severe Behçet's syndrome. Whether is safer more effective than cyclophosphamide in treating syndrome not known.MethodsIn this phase 2, Bayesian, multicenter randomized controlled trial, we assigned patients fulfilling the International Study Group's criteria who had major vascular or central nervous system involvement to receive either intravenous (5 mg/kg at weeks 0, 6, 12, 18) (0.7 g/m2 intravenously 4, 8,...
Arteritis V 1 2 3 Figure 1.Ultrasonography of the right common carotid artery (longitudinal section) shows circumferential thickening arterial wall.
<h3>Background:</h3> Behçet's syndrome (BS) significantly increases morbidity and mortality, especially among patients with vascular (i.e. vascular-BS) neurological involvement neuro-BS). Cyclophosphamide glucocorticoids have been for long the standard remission-induction therapy severe BS, but disease flares require repeated treatment courses lead to high cumulative doses. Current International guidelines advocate combination of high-dose steroids either cyclophosphamide or TNFi as...
"Retinal Vasculitis in Patients with Systemic Lupus Erythematosus." Ocular Immunology and Inflammation, 25(6), p. 891
Behçet's disease is a systemic vasculitis of unknown etiology, characterized by oral and genital aphthosis uveitis.The most common gastrointestinal location the colon ileocecal region.The diagnostic criteria were established in 1990 classification International Study Group for Disease.The digestive involvement has many similarities with inflammatory bowel diseases (IBD), Crohn's particular.We report observation 34-year-old patient no previous pathological history, admitted bleeding.Attention...